Marinus Pharmaceuticals (NASDAQ:MRNS) Given Hold Rating at Jefferies Financial Group

Marinus Pharmaceuticals (NASDAQ:MRNS)‘s stock had its “hold” rating reiterated by Jefferies Financial Group in a note issued to investors on Friday, Benzinga reports. They presently have a $0.50 price target on the biopharmaceutical company’s stock, down from their prior price target of $5.00. Jefferies Financial Group’s price target indicates a potential upside of 68.92% from the company’s current price.

MRNS has been the topic of several other research reports. StockNews.com raised shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, October 4th. JMP Securities reiterated a “market perform” rating on shares of Marinus Pharmaceuticals in a report on Thursday. Oppenheimer upgraded Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective for the company in a research note on Monday, September 23rd. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Marinus Pharmaceuticals in a research note on Wednesday, August 14th. Finally, LADENBURG THALM/SH SH downgraded shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, August 14th. Six investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $7.64.

Marinus Pharmaceuticals Trading Down 82.5 %

Shares of Marinus Pharmaceuticals stock opened at $0.30 on Friday. The stock has a fifty day simple moving average of $1.57 and a 200 day simple moving average of $1.67. Marinus Pharmaceuticals has a 12-month low of $0.28 and a 12-month high of $11.26. The company has a market capitalization of $16.30 million, a P/E ratio of -0.11 and a beta of 1.14.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. The firm had revenue of $8.06 million during the quarter, compared to the consensus estimate of $9.05 million. During the same quarter in the previous year, the company earned ($0.61) EPS. On average, analysts predict that Marinus Pharmaceuticals will post -1.93 EPS for the current year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC bought a new position in Marinus Pharmaceuticals during the second quarter worth about $727,000. Wellington Management Group LLP boosted its holdings in Marinus Pharmaceuticals by 54.8% in the 4th quarter. Wellington Management Group LLP now owns 241,299 shares of the biopharmaceutical company’s stock worth $2,623,000 after buying an additional 85,455 shares during the period. Vanguard Group Inc. grew its stake in Marinus Pharmaceuticals by 5.0% in the 1st quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock valued at $25,366,000 after buying an additional 132,689 shares in the last quarter. Acadian Asset Management LLC bought a new stake in Marinus Pharmaceuticals during the 2nd quarter valued at $813,000. Finally, Hussman Strategic Advisors Inc. raised its holdings in Marinus Pharmaceuticals by 14.3% during the 2nd quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 10,500 shares during the period. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.